NZ514777A - N6 heterocyclic 5'-thio substituted adenosine derivatives - Google Patents
N6 heterocyclic 5'-thio substituted adenosine derivativesInfo
- Publication number
- NZ514777A NZ514777A NZ514777A NZ51477700A NZ514777A NZ 514777 A NZ514777 A NZ 514777A NZ 514777 A NZ514777 A NZ 514777A NZ 51477700 A NZ51477700 A NZ 51477700A NZ 514777 A NZ514777 A NZ 514777A
- Authority
- NZ
- New Zealand
- Prior art keywords
- heterocyclic
- group
- atom
- heterocyclyl
- modifying
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 4
- 150000003835 adenosine derivatives Chemical class 0.000 title abstract 2
- 229910020008 S(O) Inorganic materials 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 108010060263 Adenosine A1 Receptor Proteins 0.000 abstract 1
- 102000030814 Adenosine A1 receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000003919 adipocyte function Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000003700 epoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/454,136 US6605597B1 (en) | 1999-12-03 | 1999-12-03 | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| PCT/US2000/032721 WO2001040246A1 (en) | 1999-12-03 | 2000-12-01 | Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ514777A true NZ514777A (en) | 2004-01-30 |
Family
ID=23803455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ514777A NZ514777A (en) | 1999-12-03 | 2000-12-01 | N6 heterocyclic 5'-thio substituted adenosine derivatives |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6605597B1 (enExample) |
| EP (1) | EP1233973B1 (enExample) |
| JP (1) | JP4021195B2 (enExample) |
| KR (1) | KR100484988B1 (enExample) |
| CN (1) | CN1152042C (enExample) |
| AR (1) | AR029199A1 (enExample) |
| AT (1) | ATE254133T1 (enExample) |
| AU (3) | AU4138701A (enExample) |
| BR (1) | BR0016126A (enExample) |
| CA (1) | CA2389264C (enExample) |
| CZ (1) | CZ20013705A3 (enExample) |
| DE (1) | DE60006576T2 (enExample) |
| DK (1) | DK1233973T3 (enExample) |
| ES (1) | ES2208437T3 (enExample) |
| HK (1) | HK1047941A1 (enExample) |
| HU (1) | HUP0500455A2 (enExample) |
| IL (1) | IL145903A (enExample) |
| MX (1) | MXPA01011113A (enExample) |
| NO (1) | NO20015373L (enExample) |
| NZ (1) | NZ514777A (enExample) |
| PT (1) | PT1233973E (enExample) |
| TR (2) | TR200301971T4 (enExample) |
| TW (1) | TWI249536B (enExample) |
| WO (2) | WO2001040243A2 (enExample) |
| ZA (1) | ZA200204380B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| CA2439222C (en) | 2000-02-23 | 2009-07-14 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| GB2372742A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
| GB2372741A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,8-Disubstituted adenosine derivatives and their different uses |
| US6946449B2 (en) * | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| PL372145A1 (en) * | 2002-02-19 | 2005-07-11 | Cv Therapeutics, Inc. | Partial and full agonists of a sb 1 /sb adenosine receptors |
| RU2332220C2 (ru) * | 2002-04-18 | 2008-08-27 | Си Ви Терапьютикс, Инк. | Способ снижения частоты сердечных сокращений, включающий введение агониста рецептора аденозина а1 вместе с бета-блокатором, блокатором кальциевых каналов или сердечным гликозидом |
| AU2003259264A1 (en) * | 2002-07-29 | 2004-02-16 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| KR20050097971A (ko) | 2003-02-03 | 2005-10-10 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ₁아데노신 수용체의 부분 및 전 작용제 |
| US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| AU2004284098B2 (en) | 2003-10-21 | 2009-07-16 | Inspire Pharmaceuticals, Inc. | Tetrahydro-furo [3,4-d] dioxole compounds and compositions and method for inhibiting platelet aggregation |
| US7749980B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Non-nucleotide compositions and method for treating pain |
| US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| DK1682537T3 (da) * | 2003-11-05 | 2012-07-09 | Sarcode Bioscience Inc | Modulatorer af celleadhæsion |
| JP2008517063A (ja) | 2004-10-20 | 2008-05-22 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ａアデノシンレセプターアゴニストの使用 |
| US7932376B2 (en) | 2005-05-05 | 2011-04-26 | Inspire Pharmaceuticals, Inc. | Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation |
| ES2530780T3 (es) * | 2005-05-17 | 2015-03-05 | Sarcode Bioscience Inc | Composiciones y métodos para el tratamiento de trastornos oculares |
| JP5203214B2 (ja) * | 2005-11-30 | 2013-06-05 | イノテック ファーマシューティカルズ コーポレイション | プリン化合物およびその使用方法 |
| WO2007092372A1 (en) | 2006-02-03 | 2007-08-16 | Cv Therapeutics, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
| EP2021350B1 (en) | 2006-03-21 | 2016-12-21 | Rheinische Friedrich-Wilhelms-Universität Bonn | Phosphorylated a2a receptor agonists |
| EP2068850A1 (en) * | 2006-06-22 | 2009-06-17 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| CN101511366B (zh) * | 2006-09-01 | 2011-12-28 | 吉利德帕洛阿尔托股份有限公司 | 在心肌显像方法期间用于增加患者耐受性的方法和组合物 |
| CA2663361A1 (en) * | 2006-09-29 | 2008-04-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
| EP2099360A2 (en) * | 2007-01-03 | 2009-09-16 | CV Therapeutics Inc. | Myocardial perfusion imaging |
| CA3105972A1 (en) | 2007-10-19 | 2009-04-30 | Novartis Ag | Compositions and methods for treatment of diabetic retinopathy |
| US20110064671A1 (en) | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
| JP2011521896A (ja) * | 2008-04-15 | 2011-07-28 | サーコード コーポレイション | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
| JP2011516607A (ja) * | 2008-04-15 | 2011-05-26 | サーコード コーポレイション | 胃腸系へのｌｆａ−１アンタゴニストの送達 |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| WO2010037122A1 (en) * | 2008-09-29 | 2010-04-01 | Gilead Palo Alto, Inc. | Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods |
| WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| CN101934559B (zh) * | 2010-08-12 | 2013-04-17 | 中国电子科技集团公司第四十五研究所 | 具有压力调节机构的砂浆供给装置 |
| WO2014018748A1 (en) | 2012-07-25 | 2014-01-30 | Sarcode Bioscience Inc. | Lfa-1 inhibitor and polymorph thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4373097A (en) | 1981-04-27 | 1983-02-08 | Bioresearch S.R.L. | Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| EP0764639A4 (en) * | 1994-06-09 | 1997-10-01 | Ss Pharmaceutical Co | 4-CHINOLINONE DERIVATIVE OR ITS SALT |
| US5789416B1 (en) * | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723566D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
-
1999
- 1999-12-03 US US09/454,136 patent/US6605597B1/en not_active Expired - Fee Related
-
2000
- 2000-11-30 WO PCT/US2000/042509 patent/WO2001040243A2/en not_active Ceased
- 2000-11-30 AU AU41387/01A patent/AU4138701A/en not_active Abandoned
- 2000-12-01 DK DK00980919T patent/DK1233973T3/da active
- 2000-12-01 TR TR2003/01971T patent/TR200301971T4/xx unknown
- 2000-12-01 BR BR0016126-8A patent/BR0016126A/pt not_active Application Discontinuation
- 2000-12-01 ES ES00980919T patent/ES2208437T3/es not_active Expired - Lifetime
- 2000-12-01 CA CA002389264A patent/CA2389264C/en not_active Expired - Fee Related
- 2000-12-01 CN CNB008139334A patent/CN1152042C/zh not_active Expired - Fee Related
- 2000-12-01 DE DE60006576T patent/DE60006576T2/de not_active Expired - Lifetime
- 2000-12-01 HK HK02109274.6A patent/HK1047941A1/zh unknown
- 2000-12-01 NZ NZ514777A patent/NZ514777A/xx active Application Filing
- 2000-12-01 AT AT00980919T patent/ATE254133T1/de not_active IP Right Cessation
- 2000-12-01 JP JP2001541001A patent/JP4021195B2/ja not_active Expired - Fee Related
- 2000-12-01 MX MXPA01011113A patent/MXPA01011113A/es active IP Right Grant
- 2000-12-01 WO PCT/US2000/032721 patent/WO2001040246A1/en not_active Ceased
- 2000-12-01 HU HU0500455A patent/HUP0500455A2/hu unknown
- 2000-12-01 CZ CZ20013705A patent/CZ20013705A3/cs unknown
- 2000-12-01 AU AU18117/01A patent/AU1811701A/en not_active Abandoned
- 2000-12-01 KR KR10-2002-7007097A patent/KR100484988B1/ko not_active Expired - Fee Related
- 2000-12-01 TR TR2001/03129T patent/TR200103129T2/xx unknown
- 2000-12-01 EP EP00980919A patent/EP1233973B1/en not_active Expired - Lifetime
- 2000-12-01 AR ARP000106398A patent/AR029199A1/es unknown
- 2000-12-01 PT PT00980919T patent/PT1233973E/pt unknown
- 2000-12-02 TW TW089125680A patent/TWI249536B/zh active
-
2001
- 2001-10-11 IL IL145903A patent/IL145903A/en not_active IP Right Cessation
- 2001-10-12 AU AU79383/01A patent/AU761029B2/en not_active Ceased
- 2001-11-01 US US09/980,533 patent/US20050054605A1/en not_active Abandoned
- 2001-11-02 NO NO20015373A patent/NO20015373L/no not_active Application Discontinuation
-
2002
- 2002-05-31 ZA ZA200204380A patent/ZA200204380B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ514777A (en) | N6 heterocyclic 5'-thio substituted adenosine derivatives | |
| BR9801020A (pt) | Derivados de azaindol-etilamina como agentes de ligação do receptor de acetilcolina nicotìnico. | |
| Leschke et al. | Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogs | |
| WO1995014007B1 (en) | Phenyl-alkyl imidazoles as h3-receptor antagonists | |
| CA2123403A1 (en) | Acyclic ethylenediamine derivatives as substance p receptor antagonists | |
| MY136270A (en) | Processes and intermediates for preparing anti-cancer compounds | |
| EP1221443A4 (en) | SUBSTITUTED IMIDAZOLINE DERIVATIVES | |
| NZ520071A (en) | 4-aminopiperidine derivatives and their use as medicine | |
| EA200400452A1 (ru) | Производные 3-замещенных 4-пиримидонов | |
| GEP20022676B (en) | 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors | |
| CA2318349A1 (en) | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | |
| BRPI0510598A (pt) | compostos de amida de aril ou heteroaril substituìdos | |
| CA2131797A1 (en) | Condensed indole derivatives as 5ht4-receptor antagonists | |
| EA200400453A1 (ru) | Производные 3-замещенных 4-пиримидонов | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| PL368409A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a? receptor and their use as medicaments | |
| TR200100378T2 (tr) | P-maddesi aşırısının aracılık ettiği hastalıkların tedavisindeki ilaç | |
| BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| IL132474A (en) | 3,4-dihydrothienopyrimidine-4-(thi) ones for combating plant fungi and a novel such compound | |
| MXPA02011418A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico. | |
| KR920002604A (ko) | 디카르복스이미드, 그의 제조 방법 및 제초제로서의 그의 용도 | |
| WO1998009953A3 (de) | Azinyloxy- und phenoxy-diaryl-carbonsäure derivate, deren herstellung und deren verwendung als gemischte eta/etb endothelin-rezeptorantagonist | |
| BR0016951A (pt) | Derivado de fenilpiperazinil, composto, composição farmacêutica, uso do mesmo, método de tratamento | |
| ATE450496T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| KR880005132A (ko) | 4,5-디히드로 및 4,5,6,7-테트라히드로피라졸로[1,5-a]피리미딘, 그 제조방법 및 이를 함유하는 치료용 조성물질 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENP | Pct: late entry into national phase requested |
Effective date: 20011012 |
|
| ASS | Change of ownership |
Owner name: CV THERAPEUTICS, INC., US Free format text: OLD OWNER(S): CV THERAPEUTICS, INC.; PRABHA N. IBRAHIM |
|
| LENP | Pct: late entry into national phase granted |
Effective date: 20011012 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |